Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Santini D, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Santoni M, Tudini M, Rijavec E, Filetti M, Catino A, Pizzutilo P, Sala L, Citarella F, Marco R, Torniai M, Cantini L, Targato G, Sforza V, Nigro O, Ferrara MG, D'Argento E, Buti S, Bordi P, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Della Gravara L, Dal Bello MG, Belderbos RA, Bironzo P, Carnio S, Ricciardi S, Grieco A, De Toma A, Proto C, Friedlaender A, Cantale O, Ricciuti B, Addeo A, Metro G, Ficorella C, Porzio G. Cortellini A, et al. Among authors: gelibter a. Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9. Epub 2020 May 30. Cancer Immunol Immunother. 2020. PMID: 32474768 Free PMC article.
Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials.
Ferretti G, Bria E, Giannarelli D, Felici A, Papaldo P, Fabi A, Di Cosimo S, Ruggeri EM, Milella M, Ciccarese M, Cecere FL, Gelibter A, Nuzzo C, Cognetti F, Terzoli E, Carlini P. Ferretti G, et al. Among authors: gelibter a. Br J Cancer. 2006 Jun 19;94(12):1789-96. doi: 10.1038/sj.bjc.6603194. Epub 2006 May 30. Br J Cancer. 2006. PMID: 16736002 Free PMC article.
Aromatase inhibitors in post-menopausal metastatic breast carcinoma.
Carlini P, Bria E, Giannarelli D, Felici A, Papaldo P, Fabi A, Ruggeri EM, Milella M, Nuzzo C, Cecere FL, Gelibter A, Pino MS, Nisticò C, Cuppone F, Metro G, Terzoli E, Cognetti F, Ferretti G. Carlini P, et al. Among authors: gelibter a. Expert Opin Investig Drugs. 2007 Jul;16(7):1023-36. doi: 10.1517/13543784.16.7.1023. Expert Opin Investig Drugs. 2007. PMID: 17594187 Review.
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Fabi A, Metro G, Papaldo P, Mottolese M, Melucci E, Carlini P, Sperduti I, Russillo M, Gelibter A, Ferretti G, Tomao S, Milella M, Cognetti F. Fabi A, et al. Among authors: gelibter a. Cancer Chemother Pharmacol. 2008 Sep;62(4):717-25. doi: 10.1007/s00280-007-0650-1. Epub 2007 Dec 6. Cancer Chemother Pharmacol. 2008. PMID: 18071704 Clinical Trial.
114 results